Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2014

View Archived Issues

Phase II data show limited single-agent activity with ganetespib in metastatic pancreatic cancer

Axon to perform extension study of phase I trial of Alzheimer's disease vaccine candidate

FDA accepts protocol amendment to phase III trial of aldoxorubicin

Investigations in murine knockout models identify the transcriptional activity underlying dermatitis

A quantifiable approach to determine TIL in tumors

Development of a portable microchip blood analyzer for diagnostic white blood cell counts

Dolutegravir approved in Europe for the treatment of HIV

Novel EP4 receptor antagonists presented by Eli Lilly

BioMarin to purchase Repligen's histone deacetylase inhibitor library

Hanmi Pharmaceutical designs new CSF-1R inhibitors

TetraLogic Pharmaceuticals collaborates with Walter and Eliza Hall Institute of Medical Research

Gilead Sciences divulges novel JAK inhibitors

Activity limited with trebananib plus sorafenib in hepatocellular carcinoma

Roche synthesizes new BACE1 inhibitors for Alzheimer's disease

Par Pharmaceutical to acquire JHP Pharmaceuticals

Poxel presents new AMPK activators for diabetes and other disorders

Kolltan Pharmaceuticals treats first patient in phase I study of KTN-3379

Cadila Healthcare synthesizes novel PCSK9 inhibitors

Celsion begins development program for ThermoDox in brain tumors

NuPathe terminates merger agreement with Endo Health, forms agreement with Teva

Phase I trial of Cortice's lead candidate for mild to moderate Alzheimer's disease begins enrollment

AstraZeneca and BMS gain E.U. approval for Xigduo in type 2 diabetes

Vical begins patient recruitment for phase I/II trial of two experimental herpes vaccines

PIQUR Therapeutics launches phase I study of PQR-309

Enrollment begins in phase I trial of Arno Therapeutics' lead compound in solid tumors

MD Anderson and Johnson & Johnson Innovation to collaborate on anticancer immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...